Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
  • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D249/14—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
  • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
  • C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Definitions

• This invention relates to novel heterocyclic derivatives having action on histamine receptors, to processes for the preparation thereof, to pharmaceutical compositions containing them and to their use in therapeutics.
• Certain novel heterocyclic derivatives have now been found which have potent activity as H 2 -antagonists. These compounds, which are more particularly described below, for example show inhibition of the secretion of gastric acid when this is stimulated via histamine receptors (Ash and Schild, Brit. J. Pharmacol, Chemother, 1966, 27, 427). Their ability to do so can be demonstrated in the perfused rat stomach using the method described in German Offenlegungsschrift No. 2,734,070, modified by the use of sodium pentobarbitone (50 mg/kg) as anaesthetic instead of urethane, and in conscious dogs equipped with Heidenhain pouches using the method described by Black et al, Nature 1972 236, 385.
• Compounds with histamine H 2 -blocking activity may be used in the treatment of conditions where there is a hypersecretion of gastric acid, particularly in gastric and peptic ulceration, as a prophylactic measure in surgical procedures, and in the treatment of allergic and inflammatory conditions where histamine is a known mediator.
• they may be used for example, either alone, or in combination with other active ingredients in the treatment of allergic and inflammatory conditions of the skin.
• the present invention provides compounds of the general formula (I) ##STR3## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which
• R 1 and R 2 which may be the same or different, each represent hydrogen, C 1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R 1 and R 2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C 1-3 alkyl groups, e.g. methyl, or a hydroxy group and/or may contain another heteroatom, e.g. oxygen or sulphur,
• Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms;
• Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R 7 adjacent to the group ##STR4## or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions;
• R 7 represents halogen or C 1-4 alkyl which may be substituted by hydroxy or C 1-4 alkoxy;
• X represents --CH 2 --, ##STR5## --O-- or --S-- where
• R 6 represents hydrogen or methyl
• n zero, 1 or 2;
• n 2, 3 or 4;
• R 3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl or aryl;
• R 4 and R 5 which may be the same or different, each represent hydrogen, alkyl, alkyl substituted by hydroxy or C 1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl or R 4 and R 5 may together with the nitrogen atom to which they are attached form a 5 to 7-membered saturated heterocyclic ring which may contain another heteroatom, e.g. oxygen, or the group ##STR6## or R 4 and R 5 taken together may represent the group ⁇ CR 8 R 9 where R 8 represents aryl or heteroaryl and R 9 represents hydrogen or alkyl.
• X represents an oxygen atom or ##STR7## and n is zero, then Q only represents a benzene ring.
• alkyl ⁇ as a group or part of a group means that the group is straight or branched and has unless otherwise stated preferably 1 to 6 carbon atoms, and in particular 1 to 4 carbon atoms e.g. methyl or ethyl and the terms ⁇ alkenyl ⁇ and ⁇ alkynyl ⁇ mean that the group has preferably 3 to 6 carbon atoms.
• ⁇ cycloalkyl ⁇ means that the group has 3 to 8 carbon atoms.
• ⁇ aryl ⁇ as a group or part of a group preferably means phenyl or substituted phenyl, for example phenyl substituted with one or more C 1-3 alkyl or C 1-3 alkoxy groups or halogen atoms.
• heteroaryl ⁇ as a group or part of a group preferably means pyridyl or substituted pyridyl, e.g. pyridyl substituted with one or more C 1-3 alkyl groups.
• the invention provides compounds of the formula (I) and physiologically acceptable salts, hydrates and bioprecursors thereof, in which
• R 1 and R 2 which may be the same or different, each represent hydrogen, C 1-6 alkyl, cycloalkyl, C 3-6 alkenyl, aralkyl or C 1-6 alkyl substituted by alkoxy, alkylamino or dialkylamino, or R 1 and R 2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may contain oxygen;
• Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms
• Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R 7 adjacent to the group R 1 R 2 N-Alk-, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- positions;
• R 7 represents C 1-4 , alkyl which may be substituted by hydroxy or C 1-4 alkoxy;
• X represents --CH 2 --, --O-- or --S--;
• n zero, 1 or 2;
• n 2, 3 or 4;
• R 3 represents hydrogen, C 1-6 alkyl, C 3-6 alkenyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl, aryl or aralkyl;
• R 4 and R 5 which may be the same or different, each represent hydrogen or C 1-6 alkyl
• the invention includes the compounds of formula (I) in the form of physiologically acceptable salts with inorganic and organic acids.
• Particularly useful salts include hydrochlorides, hydrobromides and sulphates; acetates, maleates, succinates, citrates and fumarates.
• the compounds of formula (I) and their salts may also form hydrates, which hydrates are also to be considered as part of the invention.
• the compounds of formula (I) can exhibit tautomerism and the formula is intended to cover all tautomers. Where optical isomers may exist the formula is intended to cover all diastereoisomers and optical enantiomers.
• compositions containing at least one compound according to the invention adapted for use in human or veterinary medicine.
• Such compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.
• Such compositions may also contain if required other active ingredients, e.g. H 1 -antagonists.
• the compounds according to the invention may be formulated for oral, buccal, topical, parenteral or rectal administration. Oral administration is preferred.
• the pharmaceutical composition may take the form of for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
• the composition may take the form of tablets or lozenges formulated in conventional manner.
• the compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion.
• Formulations for injection may be presented in unit dosage form in ampoules, or in multi-dose containers, with an added preservative.
• the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
• the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water before use.
• the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or othe glyceride.
• the compounds of the invention may be formulated as ointments, creams, gels, lotions, powders or sprays.
• Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable pharmaceutical excipients.
• Lotions may be formulated with an aqueous or oily base and will include the necessary adjustments to ensure pharmaceutically acceptable products.
• Spray compositions may, for example, be formulated as aerosols which may be pressurised by means of a suitable agent such as dichlorofluoromethane or trichlorofluoromethane or may be delivered by means of a hand-operated atomizer.
• a convenient daily dosage regime of the compounds according to the invention would be 1 to 6 doses to the total of some 5 mg to 2 g per day, preferably 5 to 500 mg per day.
• the total of m+n is 3 or 4, more preferably 3.
• n is preferably 1 and m is preferably 2.
• n is preferably zero and m is preferably 3 or 4, more preferably 3.
• Q is a furan ring optionally substituted by the group R 7 , where R 7 represents C 1-3 alkyl optionally substituted by alkoxy or is a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions.
• Alk represents a methylene, ethylene or propylene group.
• R 1 represents hydrogen or C 1-4 alkyl and R 2 represents C 3-5 alkenyl or alkynyl, C 5-7 cycloalkyl, benzyl, C 1-8 alkyl, or C 1-4 alkyl substituted by C 1-3 alkoxy, hydroxy, diC 1-3 alkylamino or trifluoromethyl or R 1 and R 2 together with the nitrogen atom to which they are attached form an alicyclic heterocyclic ring with 5 to 8 members and optionally containing one double bond and/or substituted by hydroxy or one or two C 1-3 alkyl group(s).
• R 3 represents hydrogen or C 1-4 alkyl or hydroxyalkyl.
• R 4 represents hydrogen or C 1-5 alkyl optionally substituted by a phenyl, pyridyl, hydroxy or C 1-3 alkoxy group and R 5 represents hydrogen or C 1-3 alkyl or R 4 and R 5 together with the nitrogen atom to which they are attached represent a C 5-7 saturated heterocyclic ring or R 4 and R 5 together represent the group ⁇ CHR 8 where R 8 represents a phenyl or pyridyl group.
• R 1 and R 2 together with the nitrogen atom to which they are attached form a heterocyclic ring this ring may be pyrrolidine, piperidine optionally substituted in the 4-position by C 1-3 alkyl or hydroxy, tetrahydropyridine, morpholine, 2,6-dialkylmorpholine, hexamethyleneimine or heptamethyleneimine.
• R 1 and R 2 both represent C 1-3 alkyl groups and when present R 7 preferably represents a C 1-3 alkyl group optionally substituted with a C 1-3 alkoxy group n is 1, X is sulphur and m is 2. More preferably Q represents a substituted furan group in which R 7 represents a C 1-3 alkyl group, in particular methyl, which may be optionally be substituted with a C 1-3 alkoxy group, in particular a methoxy group.
• Q represents a benzene ring preferably
• Alk represents a methylene, ethylene or propylene group; n is zero; X is oxygen or NH; m is 3 or 4;
• R 1 represents hydrogen or C 1-4 alkyl;
• R 2 represents a straight chain C 1-7 alkyl group which may be branched by a methyl group, or a C 1-4 alkyl group substituted by a di(C 1-3 ) alkylamino, C 1-3 alkoxy, trifluoromethyl or phenyl group or
• R 2 represents a C 5-7 cycloalkyl group or a C 3-5 alkenyl group or R 1 and R 2 together with the nitrogen atom to which they are attached form a 5 to 8 membered alicyclic heterocyclic ring which may be saturated or contain at least one double bond, or be saturated and substituted by one or more C 1-3 alkyl e.g.
• R 3 is H or C 1-2 alkyl or hydroxyethyl
• R 4 represents hydrogen or C 1-3 alkyl optionally substituted by a phenyl or pyridyl group
• R 5 represents hydrogen or C 1-3 alkyl or R 4 and R 5 together represent the group ⁇ CHR 8 where R 8 is phenyl or pyridyl.
• R 1 and R 2 represent C 1-3 alkyl, e.g. methyl, or R 1 represents hydrogen and R 2 represents C 1-7 alkyl, e.g. methyl, propyl, butyl, secondary butyl and n-heptyl, or C 3-5 alkenyl, e.g. allyl or C 5-7 cycloalkyl, e.g. cyclohexyl, or R 1 and R 2 together with the nitrogen atom to which they are attached represent a 5 to 7 membered alicyclic heterocyclic ring which may be saturated, or contain a double bond, or be saturated and substituted by one C 1-3 alkyl group e.g.
• methyl in particular pyrrolidine, piperidine optionally substituted in the 4-position by a methyl group; or tetrahydropyridine or hexamethyleneimine;
• R 3 represents hydrogen, methyl, ethyl or hydroxyethyl;
• R 4 and R 5 both represent hydrogen or ethyl or R 4 and R 5 together represent the group ⁇ CHR 8 where R 8 represents phenyl or 4-pyridyl.
• preferred compounds in which Q is benzene are those in which it is incorporated into the rest of the molecule through bonds at the 1 and 3 positions and in which Alk represents methylene, n is zero, X is oxygen and m is 3.
• Particularly preferred compounds of the invention are those in which R 3 represents methyl and R 4 and R 5 represent hydrogen. Particularly preferred compounds are:
• a phthalimide group may be cleaved by treatment with a hydrazine e.g. hydrazine hydrate or a primary amine for example methylamine; benzyl or benzyloxycarbonyl derivatives may be cleaved by hydrogenolysis in the presence of a catalyst, e.g. palladium, and trichloroethoxycarbonyl derivatives may be cleaved by treatment with zinc dust.
• a hydrazine e.g. hydrazine hydrate or a primary amine for example methylamine
• benzyl or benzyloxycarbonyl derivatives may be cleaved by hydrogenolysis in the presence of a catalyst, e.g. palladium
• trichloroethoxycarbonyl derivatives may be cleaved by treatment with zinc dust.
• R 4 and R 5 are hydrogen can be prepared by cyclising a compound of formula (II) ##STR9## in which R 1 , R 2 , Alk, Q, n, X, m and R 3 are as defined in formula (I) or are groups convertible thereto and Z represents two hydrogen atoms.
• R 3 is as defined in formula (I) and Z represents two hydrogen atoms.
• the reaction may be carried out in the presence of a suitable solvent such as an aromatic hydrocarbon, e.g. toluene, an alkanol, e.g. ethanol or isopropanol, water or dimethylformamide at a temperature of from room temperature to reflux.
• a suitable solvent such as an aromatic hydrocarbon, e.g. toluene, an alkanol, e.g. ethanol or isopropanol, water or dimethylformamide
• compounds of formula (I) in which R 4 and R 5 are both hydrogen may also be prepared via the intermediate (II) from a diamine of formula (V)
• R 1 , R 2 , Alk, Q, n, X and m are as defined in formula (II) by reaction with a compound of formula (VI) ##STR11## in which R 3 is as defined in formula (I), L is as defined in formula (III) and Z represents two hydrogen atoms or a protecting which can readily be removed to yield two hydrogen atoms, e.g. a benzylidene group.
• the reaction may be carried out in the absence of presence of a suitable solvent, for example toluene, ethanol, methanol, isopropanol, acetonitrile or water, at a temperature from room temperature to reflux.
• a suitable solvent for example toluene, ethanol, methanol, isopropanol, acetonitrile or water
• Z is a protecting group
• Z represents a benzylidene group it may be removed with aqueous acid, e.g. hydrochloric acid, and under these conditions the intermediate (II) where Z represents two hydrogen atoms cyclises to give the compound of formula (I).
• Z represents a benzylidene group it may also be removed by heating with an amine e.g. piperidine, to give the compound of formula (I).
• the compound of formula (VI) may be prepared from a compound of formula (VII) ##STR12## in which L is as defined in formula (III) and L ' may have one of the meanings of L or may represent a lower alkyl sulphoxide group.
• the compound (VII) is reacted with the hydrazine. (IV) to give the compound of formula (VI) the reaction preferably being carried out in a solvent for example toluene, an alkanol or acetonitrile, and preferably with heating.
• Compounds of formula (I) in which R 4 and R 5 are other than the group ⁇ CR 8 9 may be prepared by cyclisation of a compound of formula (VIII) ##STR13## where V is NH and Y is sulphur, oxygen or NH or V is sulphur or oxygen and Y is NH, and in which R 1 , R 2 , Alk, Q, n, X, m, R 3 , R 4 and R 5 are as defined in formula (I) except that R 4 and R 5 are other than the group ⁇ CR 8 R 9 .
• the reaction is preferably carried out by heating the compound (VIII) in a suitable solvent such as acetonitrile or dimethylformamide.
• a compound (VIII) in which V is NH and Y is sulphur, oxygen or NH may be prepared by reacting an alkylisothiourea (IX) ##STR14## in which R 10 represents a C 1-4 alkyl group, with a semicarbazide thiosemicarbazide or aminoguanidine (X) ##STR15## in which Y is oxygen, sulphur or NH, in a suitable solvent, e.g. dimethylformamide.
• reaction may be carried out preferably with heating, optionally in the presence of a suitable solvent such as a lower alkanol, e.g. ethanol, or acetonitrile.
• a suitable solvent such as a lower alkanol, e.g. ethanol, or acetonitrile.
• R 4 and R 5 are as defined in formula (I) and are other than hydrogen or the group ⁇ CR 8 R 9 and Hal is a halogen atom.
• the reaction is preferably carried out in a suitable solvent such as acetonitrile or an aromatic hydrocarbon, e.g. benzene or toluene.
• the aminoguanidine (XII) may be prepared by the reaction of a thiourea (XIV) ##STR17## with an alkyl halide or a dialkyl sulphate in the presence of an acid to produce the alkylisothiourea (IX). Reaction of this alkylisothiourea (IX) with the hydrazine (IV) in a suitable solvent such as dimethylformamide, followed by removal of the protecting group Z where appropriate gives the aminoguanidine (XII).
• D represents R 1 R 2 Nalk--or a group convertible thereto under reducing conditions where R 1 , R 2 and Alk are as defined in formula (I);
• D' represents --CH 2 NH--or a group --CONH--or --CH ⁇ N--;
• D represents NR 4 R 5 where R 4 and R 5 are as defined in formula (I) or a group --NR 4 COR 11 in which R 4 is as defined in formula (I) and R 11 represents hydrogen, alkyl, optionally substituted by a hydroxy group or a group convertible thereto under the reducing conditions aryl, aralkyl, or alkoxy.
• compounds of formula (I) in which R 4 and R 5 are other than the group ⁇ CR 8 R 9 may be prepared by reducing compounds of formula (XVI) ##STR19## in which W represents the group --CHO or --(CH 2 ) p CONR 1 R 2 , Q, n, X, m, R 3 , R 4 , R 5 , R 1 and R 2 are as defined in formula (I) and p is zero, 1, 2, 3, 4 or 5.
• Compounds of formula (I) in which Alk represents CH 2 may be prepared from the compound (XVI) in which W represents the group --CHO by reaction with ammonia or an amine R 1 R 2 NH in a solvent e.g.
• tetrahydrofuran or an alkanol such as ethanol or methanol
• a hydride reducing agent such as an alkali or alkaline earth metal borohydride, e.g. sodium borohydride, or aluminium hydride or lithium aluminium hydride or with hydrogen and a metal catalyst e.g. palladium or platinum.
• compounds of formula (I) in which Alk is a C 1-6 alkylene group may be prepared by reduction of a compound of formula (XVI) in which W represents the group R 1 R 2 NCO(CH 2 ) p .
• the reduction may be carried out with aluminium hydride or lithium aluminium hydride in a suitable solvent such as dioxan or tetrahydrofuran.
• the compounds of formula (XVI) may be prepared from an amine of formula (XVII)
• W represents the group R 1 R 2 NCO(CH 2 ) p or a protected aldehyde group e.g. an acetal or cyclic ketal, by methods analagous to those described herein for preparing the corresponding compounds of formula (I).
• compounds of formula (I) in which R 4 and R 5 are other than the group ⁇ CR 8 R 9 may be prepared by the reduction of an amide (XVIII) ##STR20## in which R 1 , R 2 , Alk, Q, n, X, m, R 3 , R 4 and R 5 are as defined in formula (I), with a suitable reducing agent such as lithium aluminium hydride or an aluminium hydride in a solvent such as tetrahydrofuran or dioxan, at temperatures from ambient to reflux.
• a suitable reducing agent such as lithium aluminium hydride or an aluminium hydride in a solvent such as tetrahydrofuran or dioxan
• Suitable activated acid derivatives include acyl halides, mixed acid anhydrides, esters, for example alkyl esters or (1-alkyl 2-pyridinyl) esters and products formed by reaction of the carboxylic acid with a coupling agent such as carbonyldiimidazole or a carbodiimide such as dicyclohexylcarbodiimide.
• the intermediate diaminotriazole (XX) in which R 4 and R 5 are both other than hydrogen may be prepared by reaction of the carbamoyl halide (XIII) with the aminoguanidine (XXI) ##STR22## in a solvent such as benzene or acetonitrile.
• compounds of formula (I) in which R 4 and R 5 are other than the group ⁇ CR 8 R 9 may also be prepared by reduction of an imine (XXII) ##STR23## in which R 1 , R 2 , Alk, Q, n, X, m, R 3 , R 4 and R 5 are as defined in formula (I).
• Suitable reducing agents include metal hydrides such as alkali or alkaline earth metal borohydrides, e.g. sodium borohydride, in a solvent such as an alkanol, e.g.
• the imine (XXII) may also be reduced with hydrogen and a suitable metal catalyst such as platinum, in a solvent such as an alkanol, e.g. methanol or ethanol.
• the imine (XXII) may be formed by reaction of an aldehyde (XXIII)
• diaminotriazole (XX) in a suitable solvent such as benzene, toluene, ethanol or methanol, preferably with heating optionally in the presence of an acid catalyst, e.g. hydrochloric acid or p-toluene sulphonic acid.
• a suitable solvent such as benzene, toluene, ethanol or methanol, preferably with heating optionally in the presence of an acid catalyst, e.g. hydrochloric acid or p-toluene sulphonic acid.
• compounds, of formula (I) in which R 4 is --CHR 8 R 9 and R 5 represents hydrogen can be prepared by the reduction of a compound of formula (XV) as defined above in which D" represents --N ⁇ CR 8 R 9 .
• the reduction may conveniently be carried out with an alkali or alkaline earth metal borohydride such as sodium borohydride or with hydrogen and a metal catalyst such as platinum or palladium.
• compounds of formula (I) in which R 4 and R 5 are both alkenyl or alkyl optionally substituted by hydroxyl may be prepared by reacting a compound of formula (I) in which at least one of R 4 and R 5 are hydrogen with the appropriate aldehyde or ketone, followed by reduction by the procedure described above.
• compounds of formula (I) in which R 1 and/or R 5 are other than hydrogen may be prepared by reduction of a compound of formula (XV) in which D represents the group R 1 a CONR 2 Alk and/or the group D" represents the group --NR 4 COR 5 1 , where R 1 a and R 5 a have meanings such that under the conditions of the reduction the groups R 1 a CO and R 5 a CO are converted into the required groups R 1 and R 5 .
• the reduction is preferably carried out with aluminium hydride or lithium aluminium hydride in a solvent such as dioxan or tetrahydrofuran.
• the compounds of formula (XV) in which D and/or D" have the meanings R 1 a CONR 2 Alk or --NR 4 COR 5 a may be prepared by treating a compound of formula (I) in which R 1 and/or R 5 represent hydrogen with an activated derivative of the appropriate acid R 1 a CO 2 H or R 5 a CO 2 H.
• R 1 , R 2 , Alk, Q, n, X and m are as defined in formula (I) and P represents a leaving group such as mesyloxy or tosyloxy group, with the diaminotriazole (XXV) in which U represents hydrogen.
• a suitable solvent such as dimethylformamide or acetonitrile.
• Compounds of formula (XXVI) in which P represents a mesyloxy or tosyloxy group may be prepared from the corresponding alcohol (i.e. the compound of formula (XXVI) in which P represents a hydroxyl group) by reaction with the appropriate sulphonyl chloride.
• Compounds of formula (XXVI) in which P represents a hydroxyl group may for example be prepared by reduction of the corresponding acid (XIX) or an ester thereof.
• compounds of formula (I) in which n is 1 and X is sulphur may be prepared by reacting a thiol (XXVII) ##STR25## in which m, R 3 , R 4 and R 5 are as defined in formula (I), with a compound (XXVIII)
• R 1 , R 2 , Alk and Q are as defined in formula (I) and P' represents a leaving group such as halogen a hydroxyl group or an acyloxy group, e.g. acetoxy.
• the reaction is carried out in an organic solvent such as dimethylformamide in the presence of a strong base, e.g. sodium hydride.
• a strong base e.g. sodium hydride.
• P' is a hydroxyl the reaction is preferably carried out in the presence of a mineral acid such as hydrochloric acid and preferably at a temperature of 0° to 80° C.
• Compounds of formula (I) in which Q is other than benzene and Alk is methylene may be prepared by introducing a group R 1 R 2 NCH 2 into a compound of formula (XXX) ##STR27## in which n, X, m, R 3 , R 4 and R 5 are as defined in formula (I).
• a compound of formula (I) in which Q is a furan or substituted furan ring may be prepared by reacting a compound of formula (XXX) with formaldehyde and an amine R 1 R 2 NH or a salt thereof in which R 1 and R 2 are as defined in formula (I). The reaction may be carried out by reacting the amine salt with aqueous formaldehyde and the compound (XXX) or by refluxing the amine salt with paraformaldehyde and compound (XXX) in a solvent such as ethanol.
• the reaction is carried out in a solvent such as acetonitrile at an elevated temperature e.g. reflux.
• a solvent such as acetonitrile
• the compounds of formula (XXX) may be prepared by methods analogous to those already described for the compounds of formula (I).
• Compounds of formula (I) in which the groups R 4 and R 5 together represent the group ⁇ CR 8 R 9 may be prepared from compounds of formula (I) in which R 4 and R 5 are both hydrogen by reaction with an aldehyde or ketone R 8 R 9 CO in a solvent such as benzene, ethanol, or methanol. The reaction is preferably carried out with heating, e.g. at reflux.
• Compounds of formula (I) can be prepared by reacting a compound of formula (XXXIII) or a compound of formula (XXXII; in which L" is a leaving group and can represent halogen e.g. bromine, acyloxy, e.g. acetoxy, or a quaternary ammonium group) with an amine R 1 R 2 NH or R 4 R 5 NH in which R 1 , R 2 , R 4 and R 5 are as defined in formula (I). ##STR28##
• reaction of the compounds (XXXII) in which Alk, Q, n, X, m, R 3 , R 4 and R 5 are as defined in formula (I) and L" is halogen, with the amine R 1 R 2 NH can be carried out in an inert solvent such as acetonitrile, in the presence of a base e.g. potassium carbonate.
• Displacement of the chlorine atom in the compound of formula (XXXIII) may be carried out by heating with the appropriate amine at elevated temperatures.
• reaction with the amine R 1 R 2 NH may be carried out in a suitable solvent such as acetonitrile or an alkanol, e.g. ethanol, at a temperature of ambient to reflux; this reaction is particularly useful for preparing compounds in which Alk is CH 2 .
• a suitable solvent such as acetonitrile or an alkanol, e.g. ethanol
• the compounds of formula (XXXII) may be prepared by conventional methods for example from the corresponding alcohol (compound of formula (XXXII) where L" is hydroxy) or the corresponding tertiary amino compound (compound of formula (I) where R 1 and R 2 are other than hydrogen).
• the compound of formula (XXXV) may be prepared by reacting a compound of formula (XXXVI) ##STR31## with an alkyl or aralkyl halide, e.g. methyl iodide or benzyl iodide.
• the phthalimide group is cleaned by standard procedure described earlier e.g. with hydrazine.
• the compounds of formulae (III), (V) (XIV) (XI) (XVII) (XIX) and (XXVIII) may be prepared as described in German Offenlegungsschrifts Nos. 2,734,070, 2,821,410 and 2,821,409 or by methods analogous to those described in these documents.
• the aldehydes of formula (XXIII) can be made by partial reduction of acids of formula (XIX).
• T.l.c. silica gel 0.25 mm thickness/ethyl acetate: light petroleum (b.p. 60°-80°) 1:4, single spot Rf 0.35.
• Methyl iodide (1.9 g) and 1-methyl-N 5 -[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1H-1,2,4-triazole-3,5-diamine (3.9 g) in acetonitrile were stirred at room temperature for 45 min. The suspension was heated at 100° for 15 min to give the title compound as a yellow solid which was collected and washed with acetonitrile (4.6 g) m.p. 178°-179°.
• a solution of sodium nitrite (0.46 g) in water (1.5 ml) was added dropwise to a solution of 1-methyl-N 5 -[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-1H-1,2,4-triazole-3,5-diamine (2.0 g) in concentrated hydrochloric acid at 5°.
• This solution of the diazonium salt was added to a solution of cuprous chloride at 75° [prepared by adding a solution of sodium metabisulphite (0.41 g) and sodium hydroxide (0.27 g) in water (3 ml) to a hot solution of copper sulphate (1.89 g) and sodium chloride (1.61 g) in water (6 ml)].
• the drug is sieved through a 250 ⁇ m sieve, blended with the excipients and compressed using 6.5 mm and 8.0 mm diameter punches for the 20 and 40 mg strengths respectively. Tablets of other strengths may be prepared by increasing the compression weight and using punches to suit.
• the tablets may be film coated with suitable film forming materials, e.g. methyl cellulose, ethyl cellulose or hydroxypropylmethyl cellulose, using standard techniques. Alternatively the tablets may be sugar coated.
• suitable film forming materials e.g. methyl cellulose, ethyl cellulose or hydroxypropylmethyl cellulose, using standard techniques.
• the tablets may be sugar coated.
• the active ingredient is sieved through a 250 ⁇ m sieve and blended with the other materials.
• the mix is filled into No. 3 hard gelatin capsules using a suitable filling machine.
• Other doses may be prepared by increasing the fill weight and if necessary changing the capsule size to accommodate the increase.
• the drug is sieved through a 250 ⁇ m sieve and blended with the Cutina HR and lactose.
• the mixed powders are moistened with Industrial Methylated Spirits 74 O.P., granules are made, dried, screened and blended with the magnesium stearate.
• the lubricated granules are compressed using 8.5 mm punches to produce tablets with a hardness of not less than 10 Kp (Schleuniger tester).
• Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability using either dilute acid or alkali.
• the solution is prepared, clarified and filled under nitrogen into appropriate sized ampoules sealed by fusion of the glass.
• the injection is sterilised by heating in an autoclave using one of the acceptable cycles.
• the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions.
• the active ingredient, buffer, flavour, preservative and colour are dissolved in some of the water.
• the remainder of the water is heated to approximately 80° C. and the sucrose is dissolved in this and cooled.
• the two solutions are mixed, adjusted to volume and clarified by filtration.
• a 1% cream may be prepared by dispersing the finely divided active ingredient in either of the two formulae for Cetamacrogol Cream B.P.C.
• the finely divided active ingredient is suspended in the propylene glycol and this is dispersed in the molten soft paraffin. The mixture is stirred until cool.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=27257387

Family Applications (3)

Family Applications After (2)

Country Status (20)

Cited By (17)

Families Citing this family (12)

Citations (5)

Family Cites Families (10)

• 1979
  • 1979-04-20 AR AR276253A patent/AR228941A1/es active
  • 1979-04-25 CH CH3909/79A patent/CH647767A5/de not_active IP Right Cessation
  • 1979-04-25 FR FR7910459A patent/FR2432511B1/fr not_active Expired
  • 1979-04-26 US US06/033,508 patent/US4318913A/en not_active Expired - Lifetime
  • 1979-04-26 AT AT0316679A patent/AT376212B/de not_active IP Right Cessation
  • 1979-04-26 SE SE7903698A patent/SE7903698L/xx not_active Application Discontinuation
  • 1979-04-26 CA CA000326446A patent/CA1143727A/fr not_active Expired
  • 1979-04-26 AU AU46482/79A patent/AU531224B2/en not_active Ceased
  • 1979-04-26 YU YU01003/79A patent/YU100379A/xx unknown
  • 1979-04-26 DK DK173579A patent/DK173579A/da active IP Right Grant
  • 1979-04-26 DE DE19792917026 patent/DE2917026A1/de not_active Ceased
  • 1979-04-26 DE DE2954639A patent/DE2954639C2/de not_active Expired - Fee Related
  • 1979-04-26 NO NO791387A patent/NO791387L/no unknown
  • 1979-04-26 FI FI791360A patent/FI791360A/fi not_active Application Discontinuation
  • 1979-04-26 PH PH22427A patent/PH19534A/en unknown
  • 1979-04-26 ES ES479988A patent/ES8102104A1/es not_active Expired
  • 1979-04-26 NZ NZ190299A patent/NZ190299A/xx unknown
  • 1979-04-26 IT IT48856/79A patent/IT1162304B/it active
  • 1979-04-26 NL NL7903313A patent/NL7903313A/xx not_active Application Discontinuation
  • 1979-04-26 LU LU81192A patent/LU81192A1/fr unknown
  • 1979-04-30 IL IL57178A patent/IL57178A/xx unknown
• 1980
  • 1980-02-16 ES ES488677A patent/ES488677A0/es active Granted
  • 1980-02-16 ES ES488676A patent/ES488676A0/es active Granted
  • 1980-02-16 ES ES488678A patent/ES8101565A1/es not_active Expired
• 1981
  • 1981-11-24 US US06/324,440 patent/US4442110A/en not_active Expired - Fee Related
• 1983
  • 1983-01-25 YU YU00161/83A patent/YU16183A/xx unknown
• 1986
  • 1986-02-06 US US06/826,832 patent/US4764612A/en not_active Expired - Lifetime

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events